Outcomes and complications of surgery in patients with intermediate-risk neuroblastoma: experience from an Indian tertiary Cancer Centre
Image-Guided Biopsy
Male
Incidence
Infant, Newborn
India
Infant
Magnetic Resonance Imaging
Disease-Free Survival
3. Good health
Survival Rate
Tertiary Care Centers
Neuroblastoma
03 medical and health sciences
Postoperative Complications
0302 clinical medicine
Risk Factors
Child, Preschool
Positron-Emission Tomography
Humans
Female
Child
Neoplasm Staging
Retrospective Studies
DOI:
10.1007/s00383-018-4241-5
Publication Date:
2018-02-27T11:46:34Z
AUTHORS (13)
ABSTRACT
The treatment of intermediate risk (IR) neuroblastoma has evolved with the focus now on reducing the drugs, dosage, and duration of chemotherapy. The aim of this study is to present the outcomes of treatment and the complications of surgery in patients with IR neuroblastoma treated at a tertiary cancer center in India.All eligible patients with IR neuroblastoma treated between April 2005 and August 2016 were identified. The presence and number of image-defined risk factors (IDRF) before and after neoadjuvant chemotherapy were retrospectively analyzed as were the extent of surgery, complications, and outcomes.Of 282 neuroblastoma patients treated during the study period, 54 had IR neuroblastoma. Complete excision was achieved in 25 patients. There were 26 surgical complications in 22 patients with a similar incidence in patients with complete (n = 13) or incomplete (n = 13) resection (p = 0.78). After a median follow-up of 47 months, the 4-year overall and event-free survival was 91.5% and 75%, respectively. There was no difference in survival between patients who underwent complete resection versus those with incomplete resection (p = 0.9).Outcomes of IR neuroblastoma are favorable. The extent of resection does not affect the survival and complications can occur even when the resection is incomplete.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (17)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....